Welcome to our dedicated page for Jaguar Health news (Ticker: JAGX), a resource for investors and traders seeking the latest updates and insights on Jaguar Health stock.
Jaguar Health, Inc. develops plant-derived prescription medicines for gastrointestinal disease states in people and animals. Its human-health news centers on crofelemer, including Mytesi for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and rare-disease intestinal failure programs tied to microvillus inclusion disease and short bowel syndrome through Napo Pharmaceuticals and Napo Therapeutics.
Company updates also cover animal-health products such as conditionally approved Canalevia-CA1 for chemotherapy-induced diarrhea in dogs and the Neonorm franchise for gut health in animals. Recurring corporate news includes Nasdaq listing-compliance matters, reverse stock splits, warrant exercises, stockholder meetings, proxy proposals, and other capital-structure actions.
Jaguar Health (NASDAQ:JAGX) announced that CEO Lisa Conte will present virtually at the Life Sciences Virtual Investor Forum on Thursday, March 12, 2026 at 2:00 PM Eastern. Registration is available through the conference site and a replay of the webcast will be posted after the event.
Jaguar Health (NASDAQ:JAGX) said it strengthened its balance sheet by restructuring royalty and debt obligations with affiliates of Chicago Venture Partners L.P., including extinguishing 48,212 warrants.
The deal cut royalty/debt by ~10% (~$3 million), extended a secured revolving credit maturity by three years for ~$7 million, and left no affiliate-held debt maturing before July 2026. The company said it will pursue additional restructuring and continues development of its crofelemer powder-for-oral-solution program for rare-disease intestinal failure.
Jaguar Health (NASDAQ:JAGX) received a $3.0 million payment from Future Pak after Jaguar terminated the buy-back provision in its January 2026 U.S. licensing agreement for Mytesi and Canalevia-CA1. Jaguar earlier received $16.0 million of non-dilutive capital, with $2.0 million contingent and up to $20.0 million in future milestones.
Jaguar will continue manufacturing both crofelemer products while Future Pak holds U.S. marketing rights; Jaguar targets an NDA filing for MVID in H1 2027 and is pursuing Breakthrough Therapy designation.
Jaguar Health (NASDAQ:JAGX) reminded shareholders that March 2, 2026 is the record date for its one-time Special Stock Dividend, which consists of Series O convertible preferred stock. Payment is scheduled for March 4, 2026 and will be sent automatically to eligible holders with no action required.
The company said the dividend is intended to reward shareholders and provide protection against potential dilution while Jaguar explores pathways to repay and restructure existing indebtedness. The Preferred Stock will not be transferable or listed for trading.
Jaguar Health (NASDAQ:JAGX) declared a one-time Special Stock Dividend of Series O convertible preferred stock to holders of common stock and certain warrants of record on March 2, 2026, with a payment date of March 4, 2026.
The Preferred Stock will convert to common shares at the board's election or automatically on December 31, 2026, with conversion based on market price at conversion; the board cited potential debt reduction and dilution protection as drivers.
The company highlighted clinical progress for crofelemer, including a reported up to 37% reduction in weekly parenteral support in an initial pediatric MVID patient and a planned NDA filing in 1H 2027.
Jaguar Health (NASDAQ:JAGX) received an initial $16M payment from a US out-license of Mytesi and Canalevia-CA1, with up to $22M more tied to milestones. The company is refocusing on crofelemer for intestinal failure (SBS-IF and MVID), holding Orphan Drug Designation in the US and EU. Investigator-initiated proof-of-concept results showed parenteral support (PS) reductions of 12–37% in pediatric patients. Jaguar expects its placebo-controlled Phase 2 to complete in Q2 2026 and targets NDA-ready data in 12–18 months. Management presented at the Sequire Investor Summit on January 22, 2026.
Jaguar Health (NASDAQ:JAGX) said CEO Lisa Conte will present virtually at the Lytham Partners Healthcare Investor Summit on Thursday, January 15, 2026 at 3:30 PM ET. The presentation is virtual and open to registered attendees.
Investors can register via the conference registration link and a replay of the webcast will be available through the same link.
Jaguar Health (NASDAQ: JAGX) entered a U.S. license agreement with Future Pak on January 12, 2026, granting Future Pak exclusive U.S. marketing rights for Mytesi (crofelemer) and Canalevia-CA1 while Jaguar will remain the manufacturer.
Jaguar will receive an $18 million upfront payment ($16M at closing, $2M on post-closing conditions) and is eligible for up to $20 million in milestone and other future payments. The agreement includes a 12-month Jaguar right to reacquire rights for mutually agreed additional crofelemer indications upon U.S. regulatory approval. Jaguar said the deal provides non-dilutive capital to focus crofelemer development on rare-disease indications, with Phase 2 study results for MVID expected in March 2026.
Jaguar Health (NASDAQ:JAGX) highlighted an article (Dec 29, 2025) summarizing initial proof‑of‑concept results for crofelemer in pediatric intestinal failure patients in the UAE.
Key findings: parenteral support (PS) reductions ranged 12–37%—two SBS-IF patients showed 12.5–15.6% PS reduction at the highest dose over 12 weeks; one MVID patient showed up to 27% reduction over 12 weeks and up to 37% during an extension after reinitiation. Results also reported reduced loose watery stools.
The company notes PS has serious toxicities and crofelemer’s PS reductions may be disease‑modifying. Crofelemer holds Orphan Drug Designation from FDA and EMA; additional placebo‑controlled trials and an FDA meeting regarding an expedited pathway were also reported.
Jaguar Health (NASDAQ:JAGX) announced it received a $240,000 grant from the FDA Center for Veterinary Medicine on January 1, 2026 to support its Canalevia-CA1 effectiveness study for chemotherapy-induced diarrhea (CID) in dogs.
Canalevia-CA1 is conditionally approved for CID and the FDA renewed that conditional approval for a fifth and final year through December 21, 2026. Jaguar must complete and file a successful effectiveness study to obtain full veterinary drug approval for CID.